Skip to content

Dr. Laurien Paredis

Active
Private limited companyfounded 2024active for 2 yearsGenkerbaan 154, 3520 Zonhoven, BelgiumKBO/BCE: BE 1013.413.537
Summary

Dr. Laurien Paredis has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €46,577 and a net result of €32,088. Its solvency ranks better than 67% of 20,612 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Risk analysisFollow ReportCompare
Dr. Laurien ParedisActiveChecked score 90/100
Risk analysis ReportCompare

Overview

Activity
General medical practice
NACE 86210
1 site
Size
€59,767total assets 2025
Equity
€46,577
Profit
€32,088
Turnover not published (micro format)
Financial health
90 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.3%
Structure
2025 accounts 31 days early
Why 90raises risk2 changes of registered office in 24 monthslowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 4.60, cash €55,723Figures for financial year 2025 (filed 30-06-2026)Show the evidence

Checked score

Score 2025
90 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 84% of its sector peers (NACE 86, micro)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Strong
Solvency 100+27
equity 77.9% of total assets
Liquidity 93+19
short-term debt 21.5% · cash 93.2%
Profitability 100=
return on assets 53.7%
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%

About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,124 companies, NACE 86, micro)
Last 24 months 10-2025: < 0.1%lowest value 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: 0.1%▲ +0.1 percentage points vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 1.1%▲ +1.0 percentage point vs 08-2026highest value 10-2026: 0.3%▼ -0.8 percentage points vs 09-2026
Credit of up to €4,000 on 30-day terms is acceptable
Liquidity ample (current ratio 4.6, compared with 1.78 in 2024, above the usual 1.5; short-term debt: 21.5% and cash: 93.2% of total assets), and 22.1% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 82% on solvency, 79% on liquidity, 80% on profitability and 95% on growth.

The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
raises risk · 2 changes of registered office in 24 months
Belgian Official Gazette
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 4.60, cash €55,723
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed 30-06-2026)
NBB · annual accounts
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 years
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
31 days early
2024
31 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 2 accounts on average 31 days before the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
26-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2024.
KBO publications · our coverage
  1. Registered officeRegistered-office move · Power of…
  2. Annual accounts filedfinancial year 2025 · micro…
  3. Liquidity more than doubledcurrent ratio 4.60

Key points

  • One director decidessole director in office 1 View
  • Total assets 20252 financial years filed €59,767 View
  • Active since 2024founded 11-09-2024 2 years View

By topic

Financials

Financial year
2025
Total assets
€59,767
Profit
€32,088
Solvency
77.9%
Total assets▲ 97.3%
Net result
20242025
Go to Financials

Timeline

Events
6
Since
2024
Next accounts
by 31-07-2027
  1. 21-10-2025Permanent representative: Jordi De Reydt
  2. 30-06-2025Annual accounts filed
  3. 13-09-2024Incorporation
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
General medical practiceNACE 86210
Founded
11-09-2024
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Key facts about Dr. Laurien Paredis

What is the company number of Dr. Laurien Paredis?
1013.413.537. In Belgium the VAT number is the company number with BE in front: BE 1013.413.537.
Where is Dr. Laurien Paredis based?
The registered office is at Genkerbaan 154, 3520 Zonhoven.Company details
What does Dr. Laurien Paredis do?
According to the KBO register, the main activity is general medical practice (NACE 86210).
What is the legal form of Dr. Laurien Paredis?
Private limited company (BV).
When was Dr. Laurien Paredis founded?
On 11-09-2024.
Is Dr. Laurien Paredis still active?
Yes, Dr. Laurien Paredis is an active enterprise in the KBO register.
What is the turnover of Dr. Laurien Paredis?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.Financials
Is Dr. Laurien Paredis profitable?
In financial year 2025, Dr. Laurien Paredis made a profit of €32,088.
Where can I find the annual accounts of Dr. Laurien Paredis?
Dr. Laurien Paredis filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Dr. Laurien Paredis due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to Dr. Laurien Paredis

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure